Currently, there are 5.67B common shares owned by the public and among those 5.66B shares have been available to trade.
The company’s stock has a 5-day price change of 0.41% and -11.49% over the past three months. PFE shares are trading 0.72% year to date (YTD), with the 12-month market performance down to -9.12% lower. It has a 12-month low price of $24.48 and touched a high of $31.54 over the same period. PFE has an average intraday trading volume of 42.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.55%, 1.50%, and -4.25% respectively.
Institutional ownership of Pfizer Inc (NYSE: PFE) shares accounts for 67.59% of the company’s 5.67B shares outstanding.
It has a market capitalization of $151.42B and a beta (3y monthly) value of 0.61. The stock’s trailing 12-month PE ratio is 35.92, while the earnings-per-share (ttm) stands at $0.74. The company has a PEG of 3.59 and a Quick Ratio of 0.73 with the debt-to-equity ratio at 0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.19% over the week and 1.89% over the month.
Analysts forecast that Pfizer Inc (PFE) will achieve an EPS of 0.46 for the current quarter, 0.71 for the next quarter and 2.93 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.27 while analysts give the company a high EPS estimate of 0.27. Comparatively, EPS for the current quarter was 0.1 a year ago. Earnings per share for the fiscal year are expected to increase by 58.63%, and -0.92% over the next financial year. EPS should grow at an annualized rate of 10.00% over the next five years, compared to -27.43% over the past 5-year period.
Looking at the support for the PFE, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on December 10, 2024, with the firm’s price target at $29. Wolfe Research coverage for the Pfizer Inc (PFE) stock in a research note released on November 15, 2024 offered a Underperform rating with a price target of $25. Citigroup was of a view on October 25, 2024 that the stock is Neutral, while Bernstein gave the stock Mkt Perform rating on October 17, 2024, issuing a price target of $32. Daiwa Securities on their part issued Outperform rating on August 07, 2024.
